Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXFP1 | Q9HBX9 | 3/20 | 0.42 |
| ▸ | RXFP2 | Q8WXD0 | 1/20 | 0.42 |
| ▸ | ALB | P02768 | 1/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 2/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | NHERF1 | O14745 | 1/20 | 0.37 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.36 |
| ▸ | TYMS | P04818 | 1/20 | 0.36 |
| ▸ | CCKAR | P32238 | 2/20 | 0.36 |
| ▸ | CCKBR | P32239 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6834154 | 0.85 | KMT2A (0.49) | RXFP1ALBPKMKMT2AMAPT | |
| SCHEMBL6833137 | 0.84 | MAP3K5 (0.44) | RXFP1ALBPKMKMT2APOLB | |
| SCHEMBL6833897 | 0.83 | ALB (0.42) | RXFP1ALBPKMHDAC1KMT2A | |
| SCHEMBL6714056 | 0.83 | KMT2A (0.36) | RXFP1RXFP2PKMHDAC1KMT2A | |
| SCHEMBL6835708 | 0.83 | CCKAR (0.51) | NHERF1CCKARCCKBR | |
| SCHEMBL6834115 | 0.83 | ALB (0.47) | RXFP1ALBPKMKMT2AMAPT | |
| SCHEMBL6707726 | 0.82 | KMT2A (0.36) | RXFP1RXFP2PKMHDAC1KMT2A | |
| SCHEMBL6834385 | 0.82 | SERPINE1 (0.51) | RXFP1ALBKMT2ANHERF1NR1H4 | |
| SCHEMBL6830877 | 0.82 | AKR1C2 (0.48) | RXFP1ALBKMT2AMAPTNHERF1 | |
| SCHEMBL6830615 | 0.82 | ALB (0.44) | RXFP1ALBPKMKMT2APOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040110802-A1 | Antibacterial benzoic acid derivatives | PHARMACIA & UPJOHN COMPANY | 2004-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040110802-A1 | Antibacterial benzoic acid derivatives | GABRD, GABBR1, GABRA1 | RXFP1 3523/4885RXFP2 4383/4885ALB 1417/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.